KRAS and non-small cell lung carcinoma: Oncogenic KRAS point mutations lead to the permanent activation of KRAS-dependent pathways and have been identified in multiple types of cancer, most notably in pancreatic cancer, non-small cell lung cancer (NSCLC), and CRC [7,8].